MedTrace Logo

A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients

NCT02439697 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-06-04

No results posted yet for this study

Summary

This is a prospective single-arm open-labeled cohort study on dialysis patients of the conversion from Aranesp® to NESP® for the treatment of anemia. The primary outcome of the study is the haemoglobin level after conversion to NESP® after 6 months. Secondary outcomes include the variability in haemoglobin level, average weekly dose of erythropoietin, safety profile of NESP®, patients' subjective assessment of fatigue and injection pain after the conversion.

Conditions

  • Anemia
  • End Stage Renal Failure on Dialysis

Interventions

OTHER

Darbepoetin alfa

Conversion from Aranesp® to NESP®

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Maggie Ming Yee Mok, MBBS FHKAM · Queen Mary Hosptial, the University of Hong KOng

  • Tak Mao Chan, MBBS FRCP · Queen Mary Hospital, the University of Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02439697 on ClinicalTrials.gov